SILO PHARMA, INC. (SILO) earnings per share
Annual history
Fiscal years 2018 – 2025
USD / SHARE 8 PERIODS
| Period | End | Diluted | Filed |
|---|---|---|---|
| FY 2025 | 2025-12-31 | -$7.50 | 2026-03-27 |
| FY 2024 | 2024-12-31 | -$17.85 | 2025-03-28 |
| FY 2023 | 2023-12-31 | -$18.00 | 2024-03-25 |
| FY 2022 | 2022-12-31 | -$25.65 | 2023-03-24 |
| FY 2021 | 2021-12-31 | $30.00 | 2022-03-28 |
| FY 2020 | 2020-12-31 | -$37.50 | 2021-03-29 |
| FY 2018 | 2018-12-31 | -$15.00 | 2019-04-04 |
| FY 2018 | 2017-12-31 | $7.50 | 2019-04-04 |
Quarterly history
Fiscal years 2018 – 2026
USD / SHARE 30 PERIODS
| Period | End | Diluted | Filed |
|---|---|---|---|
| Q1 2026 | 2026-03-31 | -$1.80 | 2026-05-14 |
| Q4 2025 | 2025-12-31 | $0.00 | 2026-03-27 |
| Q3 2025 | 2025-09-30 | -$1.80 | 2025-11-13 |
| Q2 2025 | 2025-06-30 | -$2.85 | 2025-08-13 |
| Q1 2025 | 2025-03-31 | -$3.45 | 2025-05-09 |
| Q4 2024 | 2024-12-31 | -$6.15 | 2025-03-28 |
| Q3 2024 | 2024-09-30 | -$3.30 | 2024-11-12 |
| Q2 2024 | 2024-06-30 | -$4.65 | 2024-08-13 |
| Q1 2024 | 2024-03-31 | -$4.20 | 2024-05-13 |
| Q4 2023 | 2023-12-31 | -$5.70 | 2024-03-25 |
| Q3 2023 | 2023-09-30 | -$3.15 | 2023-11-13 |
| Q1 2023 | 2023-06-30 | -$4.80 | 2023-05-12 |
| Q1 2023 | 2023-03-31 | -$4.35 | 2023-05-12 |
| Q4 2022 | 2022-12-31 | -$8.70 | 2023-03-24 |
| Q3 2022 | 2022-09-30 | -$7.35 | 2022-11-10 |
| Q2 2022 | 2022-06-30 | $0.00 | 2022-08-01 |
| Q1 2022 | 2022-03-31 | $0.00 | 2022-05-13 |
| Q4 2021 | 2021-12-31 | -$1305.00 | 2022-03-28 |
| Q3 2021 | 2021-09-30 | $47.40 | 2021-11-10 |
| Q2 2021 | 2021-06-30 | $0.00 | 2021-08-13 |
| Q1 2021 | 2021-03-31 | $0.00 | 2021-05-17 |
| Q4 2020 | 2020-12-31 | -$7.50 | 2021-03-29 |
| Q3 2020 | 2020-09-30 | -$7.50 | 2020-11-05 |
| Q3 2019 | 2019-09-30 | -$7.50 | 2019-11-13 |
| Q2 2019 | 2019-06-30 | -$7.50 | 2019-08-13 |
| Q1 2019 | 2019-03-31 | -$7.50 | 2019-05-14 |
| Q4 2018 | 2018-12-31 | -$7.50 | 2019-04-04 |
| Q3 2018 | 2018-09-30 | $0.00 | 2018-11-14 |
| Q2 2019 | 2018-06-30 | -$7.50 | 2019-08-13 |
| Q1 2019 | 2018-03-31 | $0.00 | 2019-05-14 |
Methodology
Annual rows come from the filer's 10-K and Q1–Q3 rows from the matching 10-Q; Q4 is derived as full-year minus nine-month YTD because XBRL doesn't tag Q4 as its own period. EPS Basic and EPS Diluted are reported directly by the filer. Per-share values are split-adjusted to the current share count (2 split s since 2022).
For the exact XBRL concepts and formulas, see the methodology reference for EPS, FCF per share, the Q4 derivation, and split adjustment.
SILO CIK 0001514183 Source: EDGAR filings · all facts